ArticleBMB reports2026
Multi-omics identification of a microbial metabolite driving OXPHOS-mediated epithelial damage in experimental autoimmune encephalomyelitis.
Article in BMB reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bowel syndrome is a prevalent and debilitating symptom in patients with multiple sclerosis (MS), substantially impairing their quality of life. However, the underlying mechanisms of MS development remain poorly understood. In this study, we demonstrated that intestinal epithelial cells (IECs) and the mucosal barrier were disrupted during experimental autoimmune encephalomyelitis (EAE) induction, driven by the inhibition of mitochondrial oxidative phosphorylation (OXPHOS). Proteomic analysis confirmed alterations in OXPHOS complexes, with a pronounced decrease in the expression of cytochrome c oxidase and ATP synthase subunits in small intestinal epithelial cells (sIECs). We identified a gut microbiota-derived metabolite that induces IEC dysfunction by downregulating OXPHOS protein complexes. Specifically, metabolomic analysis revealed an enrichment of phenyllactic acid (PLA), a phenolic acid typically produced by Lactobacillus murinus, in the cecal contents of EAE mice. Our findings indicate that PLA actively downregulates OXPHOS complexes and restrains maximal mitochondrial respiration. Using a multi-omics approach, this study elucidated a potential mechanism by which gut microbiota dysbiosis observed in EAE mice compromises IEC integrity and disrupts the mucosal barrier. [BMB Reports 2026; 59(2): 151-160].
Indexed as
Identifiers
41407324PMC12936601What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.